nodes	percent_of_prediction	percent_of_DWPC	metapath
Betamethasone—psoriasis—skin cancer	0.512	1	CtDrD
Betamethasone—PTGS2—skin cancer	0.219	1	CbGaD
Betamethasone—ABCB1—Vismodegib—skin cancer	0.0317	0.21	CbGbCtD
Betamethasone—CYP3A4—Imiquimod—skin cancer	0.0274	0.182	CbGbCtD
Betamethasone—CYP3A4—Temozolomide—skin cancer	0.0274	0.182	CbGbCtD
Betamethasone—CYP3A4—Vismodegib—skin cancer	0.019	0.126	CbGbCtD
Betamethasone—ABCB1—Dactinomycin—skin cancer	0.0166	0.11	CbGbCtD
Betamethasone—CYP3A4—Vemurafenib—skin cancer	0.015	0.0995	CbGbCtD
Betamethasone—ABCB1—Docetaxel—skin cancer	0.00859	0.057	CbGbCtD
Betamethasone—CYP3A4—Docetaxel—skin cancer	0.00515	0.0341	CbGbCtD
Betamethasone—PLA2G1B—blood vessel—skin cancer	0.00266	0.0887	CbGeAlD
Betamethasone—Fluocinonide—SMO—skin cancer	0.00147	0.888	CrCbGaD
Betamethasone—PTGS2—leg—skin cancer	0.00143	0.0478	CbGeAlD
Betamethasone—PLA2G1B—connective tissue—skin cancer	0.00136	0.0455	CbGeAlD
Betamethasone—PLA2G1B—epithelium—skin cancer	0.00129	0.0432	CbGeAlD
Betamethasone—PTGS2—hindlimb—skin cancer	0.00128	0.0427	CbGeAlD
Betamethasone—NR3C2—Preimplantation Embryo—PADI6—skin cancer	0.00126	0.23	CbGpPWpGaD
Betamethasone—PGR—blood vessel—skin cancer	0.00122	0.0408	CbGeAlD
Betamethasone—PTGS2—appendage—skin cancer	0.0011	0.0366	CbGeAlD
Betamethasone—PLA2G1B—female reproductive system—skin cancer	0.00096	0.0321	CbGeAlD
Betamethasone—NR3C2—nipple—skin cancer	0.000951	0.0318	CbGeAlD
Betamethasone—PTGS2—skin epidermis—skin cancer	0.000913	0.0305	CbGeAlD
Betamethasone—NR3C1—nerve—skin cancer	0.000898	0.03	CbGeAlD
Betamethasone—PGR—nipple—skin cancer	0.000884	0.0295	CbGeAlD
Betamethasone—PLA2G1B—head—skin cancer	0.000802	0.0268	CbGeAlD
Betamethasone—NR3C2—connective tissue—skin cancer	0.000674	0.0225	CbGeAlD
Betamethasone—PTGS2—endothelium—skin cancer	0.000662	0.0221	CbGeAlD
Betamethasone—PGR—connective tissue—skin cancer	0.000627	0.0209	CbGeAlD
Betamethasone—PTGS2—blood vessel—skin cancer	0.000611	0.0204	CbGeAlD
Betamethasone—PGR—epithelium—skin cancer	0.000595	0.0199	CbGeAlD
Betamethasone—CYP19A1—connective tissue—skin cancer	0.000564	0.0188	CbGeAlD
Betamethasone—NR3C2—mammalian vulva—skin cancer	0.000555	0.0185	CbGeAlD
Betamethasone—NR3C1—nipple—skin cancer	0.00051	0.017	CbGeAlD
Betamethasone—NR3C1—neck—skin cancer	0.000505	0.0169	CbGeAlD
Betamethasone—NR3C2—female reproductive system—skin cancer	0.000476	0.0159	CbGeAlD
Betamethasone—PGR—lymphoid tissue—skin cancer	0.000458	0.0153	CbGeAlD
Betamethasone—PGR—female reproductive system—skin cancer	0.000442	0.0148	CbGeAlD
Betamethasone—NR3C2—Preimplantation Embryo—NKX2-1—skin cancer	0.000415	0.076	CbGpPWpGaD
Betamethasone—CYP19A1—female reproductive system—skin cancer	0.000398	0.0133	CbGeAlD
Betamethasone—NR3C2—head—skin cancer	0.000397	0.0133	CbGeAlD
Betamethasone—ABCB1—blood vessel—skin cancer	0.000378	0.0126	CbGeAlD
Betamethasone—PGR—head—skin cancer	0.000369	0.0123	CbGeAlD
Betamethasone—NR3C1—connective tissue—skin cancer	0.000362	0.0121	CbGeAlD
Betamethasone—NR3C1—epithelium—skin cancer	0.000343	0.0115	CbGeAlD
Betamethasone—CYP19A1—head—skin cancer	0.000332	0.0111	CbGeAlD
Betamethasone—NR3C1—skin of body—skin cancer	0.000327	0.0109	CbGeAlD
Betamethasone—PTGS2—connective tissue—skin cancer	0.000313	0.0105	CbGeAlD
Betamethasone—NR3C1—mammalian vulva—skin cancer	0.000298	0.00995	CbGeAlD
Betamethasone—PTGS2—epithelium—skin cancer	0.000297	0.00992	CbGeAlD
Betamethasone—PTGS2—skin of body—skin cancer	0.000283	0.00944	CbGeAlD
Betamethasone—NR3C2—lymph node—skin cancer	0.000278	0.00929	CbGeAlD
Betamethasone—NR3C1—lymphoid tissue—skin cancer	0.000265	0.00883	CbGeAlD
Betamethasone—PGR—lymph node—skin cancer	0.000259	0.00864	CbGeAlD
Betamethasone—NR3C1—female reproductive system—skin cancer	0.000255	0.00852	CbGeAlD
Betamethasone—NR3C1—Glucocorticoid receptor regulatory network—KRT17—skin cancer	0.000254	0.0466	CbGpPWpGaD
Betamethasone—PLA2G1B—Fc-epsilon receptor I signaling in mast cells—RASA1—skin cancer	0.00025	0.0458	CbGpPWpGaD
Betamethasone—CYP19A1—lymph node—skin cancer	0.000233	0.00777	CbGeAlD
Betamethasone—PTGS2—lymphoid tissue—skin cancer	0.000229	0.00764	CbGeAlD
Betamethasone—PGR—Ovarian Infertility Genes—MLH1—skin cancer	0.000225	0.0413	CbGpPWpGaD
Betamethasone—PTGS2—female reproductive system—skin cancer	0.000221	0.00737	CbGeAlD
Betamethasone—NR3C1—head—skin cancer	0.000213	0.00712	CbGeAlD
Betamethasone—CYP3A4—female reproductive system—skin cancer	0.000193	0.00644	CbGeAlD
Betamethasone—Skin exfoliation—Docetaxel—skin cancer	0.000193	0.00236	CcSEcCtD
Betamethasone—Convulsion—Imiquimod—skin cancer	0.000192	0.00235	CcSEcCtD
Betamethasone—Fluid retention—Docetaxel—skin cancer	0.000192	0.00235	CcSEcCtD
Betamethasone—Hypertension—Imiquimod—skin cancer	0.000191	0.00234	CcSEcCtD
Betamethasone—Neuropathy—Docetaxel—skin cancer	0.000189	0.00232	CcSEcCtD
Betamethasone—Myalgia—Imiquimod—skin cancer	0.000188	0.00231	CcSEcCtD
Betamethasone—Anxiety—Imiquimod—skin cancer	0.000188	0.0023	CcSEcCtD
Betamethasone—Discomfort—Imiquimod—skin cancer	0.000186	0.00228	CcSEcCtD
Betamethasone—Dry skin—Fluorouracil—skin cancer	0.000186	0.00228	CcSEcCtD
Betamethasone—Sweating increased—Temozolomide—skin cancer	0.000185	0.00227	CcSEcCtD
Betamethasone—PTGS2—head—skin cancer	0.000184	0.00616	CbGeAlD
Betamethasone—Oesophagitis—Docetaxel—skin cancer	0.000184	0.00226	CcSEcCtD
Betamethasone—Decreased appetite—Vemurafenib—skin cancer	0.000184	0.00226	CcSEcCtD
Betamethasone—ABCB1—epithelium—skin cancer	0.000184	0.00614	CbGeAlD
Betamethasone—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000183	0.00224	CcSEcCtD
Betamethasone—Fatigue—Vemurafenib—skin cancer	0.000183	0.00224	CcSEcCtD
Betamethasone—NR3C1—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.000182	0.0334	CbGpPWpGaD
Betamethasone—Haemoglobin—Bleomycin—skin cancer	0.000182	0.00223	CcSEcCtD
Betamethasone—Oedema—Imiquimod—skin cancer	0.000181	0.00222	CcSEcCtD
Betamethasone—Haemorrhage—Bleomycin—skin cancer	0.000181	0.00222	CcSEcCtD
Betamethasone—Pulmonary oedema—Docetaxel—skin cancer	0.00018	0.0022	CcSEcCtD
Betamethasone—Infection—Imiquimod—skin cancer	0.000179	0.0022	CcSEcCtD
Betamethasone—Muscular weakness—Fluorouracil—skin cancer	0.000179	0.0022	CcSEcCtD
Betamethasone—Shock—Imiquimod—skin cancer	0.000178	0.00218	CcSEcCtD
Betamethasone—Nervous system disorder—Imiquimod—skin cancer	0.000177	0.00217	CcSEcCtD
Betamethasone—Tachycardia—Imiquimod—skin cancer	0.000176	0.00216	CcSEcCtD
Betamethasone—Hyperhidrosis—Imiquimod—skin cancer	0.000175	0.00214	CcSEcCtD
Betamethasone—Weight increased—Temozolomide—skin cancer	0.000173	0.00213	CcSEcCtD
Betamethasone—Weight decreased—Temozolomide—skin cancer	0.000172	0.00211	CcSEcCtD
Betamethasone—Anorexia—Imiquimod—skin cancer	0.000172	0.00211	CcSEcCtD
Betamethasone—Hyperglycaemia—Temozolomide—skin cancer	0.000172	0.00211	CcSEcCtD
Betamethasone—Thrombophlebitis—Docetaxel—skin cancer	0.000169	0.00208	CcSEcCtD
Betamethasone—Body temperature increased—Vemurafenib—skin cancer	0.000167	0.00205	CcSEcCtD
Betamethasone—Neuropathy peripheral—Temozolomide—skin cancer	0.000166	0.00204	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000165	0.00202	CcSEcCtD
Betamethasone—Insomnia—Imiquimod—skin cancer	0.000163	0.002	CcSEcCtD
Betamethasone—Paraesthesia—Imiquimod—skin cancer	0.000162	0.00199	CcSEcCtD
Betamethasone—Cardiac failure congestive—Docetaxel—skin cancer	0.000162	0.00198	CcSEcCtD
Betamethasone—Alopecia—Bleomycin—skin cancer	0.00016	0.00196	CcSEcCtD
Betamethasone—ABCB1—mammalian vulva—skin cancer	0.000159	0.00533	CbGeAlD
Betamethasone—Dyspepsia—Imiquimod—skin cancer	0.000159	0.00195	CcSEcCtD
Betamethasone—Erythema—Bleomycin—skin cancer	0.000157	0.00193	CcSEcCtD
Betamethasone—Decreased appetite—Imiquimod—skin cancer	0.000157	0.00193	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Imiquimod—skin cancer	0.000156	0.00191	CcSEcCtD
Betamethasone—Fatigue—Imiquimod—skin cancer	0.000156	0.00191	CcSEcCtD
Betamethasone—Visual disturbance—Docetaxel—skin cancer	0.000155	0.0019	CcSEcCtD
Betamethasone—Pain—Imiquimod—skin cancer	0.000155	0.0019	CcSEcCtD
Betamethasone—Acute coronary syndrome—Fluorouracil—skin cancer	0.000154	0.00189	CcSEcCtD
Betamethasone—Myocardial infarction—Fluorouracil—skin cancer	0.000153	0.00188	CcSEcCtD
Betamethasone—Neuropathy peripheral—Fluorouracil—skin cancer	0.000153	0.00188	CcSEcCtD
Betamethasone—Dermatitis bullous—Docetaxel—skin cancer	0.000153	0.00188	CcSEcCtD
Betamethasone—Haemoglobin—Temozolomide—skin cancer	0.000153	0.00188	CcSEcCtD
Betamethasone—Haemorrhage—Temozolomide—skin cancer	0.000152	0.00187	CcSEcCtD
Betamethasone—Conjunctivitis—Fluorouracil—skin cancer	0.000152	0.00186	CcSEcCtD
Betamethasone—Asthenia—Vemurafenib—skin cancer	0.000152	0.00186	CcSEcCtD
Betamethasone—Hallucination—Temozolomide—skin cancer	0.000152	0.00186	CcSEcCtD
Betamethasone—Cardiac failure—Docetaxel—skin cancer	0.00015	0.00184	CcSEcCtD
Betamethasone—Pruritus—Vemurafenib—skin cancer	0.00015	0.00184	CcSEcCtD
Betamethasone—Lethargy—Docetaxel—skin cancer	0.000149	0.00183	CcSEcCtD
Betamethasone—NR3C1—lymph node—skin cancer	0.000149	0.00498	CbGeAlD
Betamethasone—Alopecia—Dactinomycin—skin cancer	0.000149	0.00183	CcSEcCtD
Betamethasone—Feeling abnormal—Imiquimod—skin cancer	0.000149	0.00183	CcSEcCtD
Betamethasone—Gastrointestinal pain—Imiquimod—skin cancer	0.000148	0.00181	CcSEcCtD
Betamethasone—CYP19A1—Ovarian Infertility Genes—MLH1—skin cancer	0.000148	0.0271	CbGpPWpGaD
Betamethasone—Visual impairment—Temozolomide—skin cancer	0.000147	0.0018	CcSEcCtD
Betamethasone—Erythema—Dactinomycin—skin cancer	0.000147	0.0018	CcSEcCtD
Betamethasone—Ill-defined disorder—Bleomycin—skin cancer	0.000146	0.00179	CcSEcCtD
Betamethasone—Diarrhoea—Vemurafenib—skin cancer	0.000145	0.00178	CcSEcCtD
Betamethasone—Migraine—Docetaxel—skin cancer	0.000144	0.00177	CcSEcCtD
Betamethasone—Urticaria—Imiquimod—skin cancer	0.000144	0.00176	CcSEcCtD
Betamethasone—Body temperature increased—Imiquimod—skin cancer	0.000143	0.00175	CcSEcCtD
Betamethasone—Abdominal pain—Imiquimod—skin cancer	0.000143	0.00175	CcSEcCtD
Betamethasone—Eye disorder—Temozolomide—skin cancer	0.000142	0.00175	CcSEcCtD
Betamethasone—Malaise—Bleomycin—skin cancer	0.000142	0.00174	CcSEcCtD
Betamethasone—ABCB1—lymphoid tissue—skin cancer	0.000142	0.00473	CbGeAlD
Betamethasone—Haemoglobin—Fluorouracil—skin cancer	0.000141	0.00173	CcSEcCtD
Betamethasone—Haemorrhage—Fluorouracil—skin cancer	0.00014	0.00172	CcSEcCtD
Betamethasone—Dizziness—Vemurafenib—skin cancer	0.00014	0.00172	CcSEcCtD
Betamethasone—Angiopathy—Temozolomide—skin cancer	0.000138	0.0017	CcSEcCtD
Betamethasone—ABCB1—female reproductive system—skin cancer	0.000137	0.00456	CbGeAlD
Betamethasone—Ill-defined disorder—Dactinomycin—skin cancer	0.000136	0.00167	CcSEcCtD
Betamethasone—Vomiting—Vemurafenib—skin cancer	0.000135	0.00165	CcSEcCtD
Betamethasone—Alopecia—Temozolomide—skin cancer	0.000135	0.00165	CcSEcCtD
Betamethasone—Dry skin—Docetaxel—skin cancer	0.000134	0.00165	CcSEcCtD
Betamethasone—Myalgia—Bleomycin—skin cancer	0.000134	0.00164	CcSEcCtD
Betamethasone—Rash—Vemurafenib—skin cancer	0.000134	0.00164	CcSEcCtD
Betamethasone—NR3C1—Glucocorticoid receptor regulatory network—KRT5—skin cancer	0.000134	0.0245	CbGpPWpGaD
Betamethasone—Dermatitis—Vemurafenib—skin cancer	0.000133	0.00164	CcSEcCtD
Betamethasone—NR3C1—Adipogenesis—ASIP—skin cancer	0.000133	0.0244	CbGpPWpGaD
Betamethasone—Headache—Vemurafenib—skin cancer	0.000133	0.00163	CcSEcCtD
Betamethasone—Erythema—Temozolomide—skin cancer	0.000133	0.00163	CcSEcCtD
Betamethasone—Discomfort—Bleomycin—skin cancer	0.000132	0.00162	CcSEcCtD
Betamethasone—Malaise—Dactinomycin—skin cancer	0.000132	0.00162	CcSEcCtD
Betamethasone—Asthenia—Imiquimod—skin cancer	0.00013	0.00159	CcSEcCtD
Betamethasone—PTGS2—lymph node—skin cancer	0.000129	0.00431	CbGeAlD
Betamethasone—NR3C1—Endoderm Differentiation—NKX2-1—skin cancer	0.000129	0.0236	CbGpPWpGaD
Betamethasone—Oedema—Bleomycin—skin cancer	0.000128	0.00157	CcSEcCtD
Betamethasone—Anaphylactic shock—Bleomycin—skin cancer	0.000128	0.00157	CcSEcCtD
Betamethasone—Pruritus—Imiquimod—skin cancer	0.000128	0.00157	CcSEcCtD
Betamethasone—Infection—Bleomycin—skin cancer	0.000128	0.00156	CcSEcCtD
Betamethasone—Nausea—Vemurafenib—skin cancer	0.000126	0.00154	CcSEcCtD
Betamethasone—Thrombocytopenia—Bleomycin—skin cancer	0.000126	0.00154	CcSEcCtD
Betamethasone—Arrhythmia—Fluorouracil—skin cancer	0.000125	0.00154	CcSEcCtD
Betamethasone—Myalgia—Dactinomycin—skin cancer	0.000125	0.00153	CcSEcCtD
Betamethasone—Triamcinolone—PTGS2—skin cancer	0.000124	0.0755	CrCbGaD
Betamethasone—NR3C1—Glucocorticoid receptor regulatory network—KRT14—skin cancer	0.000124	0.0228	CbGpPWpGaD
Betamethasone—Alopecia—Fluorouracil—skin cancer	0.000124	0.00152	CcSEcCtD
Betamethasone—Diarrhoea—Imiquimod—skin cancer	0.000124	0.00152	CcSEcCtD
Betamethasone—Discomfort—Dactinomycin—skin cancer	0.000123	0.00151	CcSEcCtD
Betamethasone—Ill-defined disorder—Temozolomide—skin cancer	0.000123	0.00151	CcSEcCtD
Betamethasone—Anorexia—Bleomycin—skin cancer	0.000122	0.0015	CcSEcCtD
Betamethasone—Erythema—Fluorouracil—skin cancer	0.000122	0.0015	CcSEcCtD
Betamethasone—Angioedema—Temozolomide—skin cancer	0.000121	0.00149	CcSEcCtD
Betamethasone—Hypotension—Bleomycin—skin cancer	0.00012	0.00147	CcSEcCtD
Betamethasone—Oedema—Dactinomycin—skin cancer	0.00012	0.00147	CcSEcCtD
Betamethasone—Malaise—Temozolomide—skin cancer	0.00012	0.00147	CcSEcCtD
Betamethasone—Dizziness—Imiquimod—skin cancer	0.000119	0.00147	CcSEcCtD
Betamethasone—Vertigo—Temozolomide—skin cancer	0.000119	0.00146	CcSEcCtD
Betamethasone—Infection—Dactinomycin—skin cancer	0.000119	0.00146	CcSEcCtD
Betamethasone—Thrombocytopenia—Dactinomycin—skin cancer	0.000117	0.00144	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000117	0.00143	CcSEcCtD
Betamethasone—Paraesthesia—Bleomycin—skin cancer	0.000115	0.00141	CcSEcCtD
Betamethasone—Weight increased—Docetaxel—skin cancer	0.000115	0.00141	CcSEcCtD
Betamethasone—Convulsion—Temozolomide—skin cancer	0.000115	0.00141	CcSEcCtD
Betamethasone—Vomiting—Imiquimod—skin cancer	0.000115	0.00141	CcSEcCtD
Betamethasone—Weight decreased—Docetaxel—skin cancer	0.000115	0.00141	CcSEcCtD
Betamethasone—Hypertension—Temozolomide—skin cancer	0.000115	0.0014	CcSEcCtD
Betamethasone—PGR—Ovarian Infertility Genes—CDK4—skin cancer	0.000114	0.021	CbGpPWpGaD
Betamethasone—Anorexia—Dactinomycin—skin cancer	0.000114	0.0014	CcSEcCtD
Betamethasone—ABCB1—head—skin cancer	0.000114	0.00381	CbGeAlD
Betamethasone—Rash—Imiquimod—skin cancer	0.000114	0.0014	CcSEcCtD
Betamethasone—Dermatitis—Imiquimod—skin cancer	0.000114	0.0014	CcSEcCtD
Betamethasone—Headache—Imiquimod—skin cancer	0.000113	0.00139	CcSEcCtD
Betamethasone—Myalgia—Temozolomide—skin cancer	0.000113	0.00139	CcSEcCtD
Betamethasone—Anxiety—Temozolomide—skin cancer	0.000113	0.00138	CcSEcCtD
Betamethasone—Discomfort—Temozolomide—skin cancer	0.000112	0.00137	CcSEcCtD
Betamethasone—Decreased appetite—Bleomycin—skin cancer	0.000112	0.00137	CcSEcCtD
Betamethasone—Acute coronary syndrome—Docetaxel—skin cancer	0.000111	0.00137	CcSEcCtD
Betamethasone—Neuropathy peripheral—Docetaxel—skin cancer	0.000111	0.00136	CcSEcCtD
Betamethasone—Myocardial infarction—Docetaxel—skin cancer	0.000111	0.00136	CcSEcCtD
Betamethasone—Pain—Bleomycin—skin cancer	0.00011	0.00135	CcSEcCtD
Betamethasone—Conjunctivitis—Docetaxel—skin cancer	0.00011	0.00135	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000109	0.00134	CcSEcCtD
Betamethasone—Anaphylactic shock—Temozolomide—skin cancer	0.000108	0.00133	CcSEcCtD
Betamethasone—Oedema—Temozolomide—skin cancer	0.000108	0.00133	CcSEcCtD
Betamethasone—Infection—Temozolomide—skin cancer	0.000108	0.00132	CcSEcCtD
Betamethasone—Nausea—Imiquimod—skin cancer	0.000107	0.00132	CcSEcCtD
Betamethasone—PTGS2—Signaling mediated by p38-alpha and p38-beta—MITF—skin cancer	0.000107	0.0196	CbGpPWpGaD
Betamethasone—Nervous system disorder—Temozolomide—skin cancer	0.000106	0.0013	CcSEcCtD
Betamethasone—Thrombocytopenia—Temozolomide—skin cancer	0.000106	0.0013	CcSEcCtD
Betamethasone—Convulsion—Fluorouracil—skin cancer	0.000106	0.0013	CcSEcCtD
Betamethasone—Feeling abnormal—Bleomycin—skin cancer	0.000106	0.0013	CcSEcCtD
Betamethasone—Hyperhidrosis—Temozolomide—skin cancer	0.000105	0.00128	CcSEcCtD
Betamethasone—Myalgia—Fluorouracil—skin cancer	0.000104	0.00128	CcSEcCtD
Betamethasone—Decreased appetite—Dactinomycin—skin cancer	0.000104	0.00128	CcSEcCtD
Betamethasone—Fatigue—Dactinomycin—skin cancer	0.000103	0.00127	CcSEcCtD
Betamethasone—Anorexia—Temozolomide—skin cancer	0.000103	0.00127	CcSEcCtD
Betamethasone—Discomfort—Fluorouracil—skin cancer	0.000103	0.00126	CcSEcCtD
Betamethasone—Pain—Dactinomycin—skin cancer	0.000102	0.00126	CcSEcCtD
Betamethasone—Urticaria—Bleomycin—skin cancer	0.000102	0.00125	CcSEcCtD
Betamethasone—Haemoglobin—Docetaxel—skin cancer	0.000102	0.00125	CcSEcCtD
Betamethasone—Body temperature increased—Bleomycin—skin cancer	0.000101	0.00124	CcSEcCtD
Betamethasone—Haemorrhage—Docetaxel—skin cancer	0.000101	0.00124	CcSEcCtD
Betamethasone—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.0001	0.0183	CbGpPWpGaD
Betamethasone—Oedema—Fluorouracil—skin cancer	9.98e-05	0.00122	CcSEcCtD
Betamethasone—Anaphylactic shock—Fluorouracil—skin cancer	9.98e-05	0.00122	CcSEcCtD
Betamethasone—Infection—Fluorouracil—skin cancer	9.91e-05	0.00122	CcSEcCtD
Betamethasone—Feeling abnormal—Dactinomycin—skin cancer	9.86e-05	0.00121	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Temozolomide—skin cancer	9.86e-05	0.00121	CcSEcCtD
Betamethasone—Insomnia—Temozolomide—skin cancer	9.79e-05	0.0012	CcSEcCtD
Betamethasone—Gastrointestinal pain—Dactinomycin—skin cancer	9.79e-05	0.0012	CcSEcCtD
Betamethasone—Nervous system disorder—Fluorouracil—skin cancer	9.78e-05	0.0012	CcSEcCtD
Betamethasone—Thrombocytopenia—Fluorouracil—skin cancer	9.77e-05	0.0012	CcSEcCtD
Betamethasone—Visual impairment—Docetaxel—skin cancer	9.77e-05	0.0012	CcSEcCtD
Betamethasone—Tachycardia—Fluorouracil—skin cancer	9.74e-05	0.00119	CcSEcCtD
Betamethasone—Paraesthesia—Temozolomide—skin cancer	9.72e-05	0.00119	CcSEcCtD
Betamethasone—Dyspepsia—Temozolomide—skin cancer	9.53e-05	0.00117	CcSEcCtD
Betamethasone—Anorexia—Fluorouracil—skin cancer	9.51e-05	0.00117	CcSEcCtD
Betamethasone—Eye disorder—Docetaxel—skin cancer	9.47e-05	0.00116	CcSEcCtD
Betamethasone—Abdominal pain—Dactinomycin—skin cancer	9.46e-05	0.00116	CcSEcCtD
Betamethasone—Body temperature increased—Dactinomycin—skin cancer	9.46e-05	0.00116	CcSEcCtD
Betamethasone—Decreased appetite—Temozolomide—skin cancer	9.41e-05	0.00115	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Temozolomide—skin cancer	9.35e-05	0.00115	CcSEcCtD
Betamethasone—Fatigue—Temozolomide—skin cancer	9.33e-05	0.00114	CcSEcCtD
Betamethasone—Hypotension—Fluorouracil—skin cancer	9.32e-05	0.00114	CcSEcCtD
Betamethasone—Pain—Temozolomide—skin cancer	9.26e-05	0.00114	CcSEcCtD
Betamethasone—Asthenia—Bleomycin—skin cancer	9.21e-05	0.00113	CcSEcCtD
Betamethasone—Angiopathy—Docetaxel—skin cancer	9.2e-05	0.00113	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Fluorouracil—skin cancer	9.09e-05	0.00111	CcSEcCtD
Betamethasone—Pruritus—Bleomycin—skin cancer	9.08e-05	0.00111	CcSEcCtD
Betamethasone—Arrhythmia—Docetaxel—skin cancer	9.05e-05	0.00111	CcSEcCtD
Betamethasone—Insomnia—Fluorouracil—skin cancer	9.02e-05	0.00111	CcSEcCtD
Betamethasone—Paraesthesia—Fluorouracil—skin cancer	8.96e-05	0.0011	CcSEcCtD
Betamethasone—Alopecia—Docetaxel—skin cancer	8.96e-05	0.0011	CcSEcCtD
Betamethasone—Feeling abnormal—Temozolomide—skin cancer	8.92e-05	0.00109	CcSEcCtD
Betamethasone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—skin cancer	8.88e-05	0.0163	CbGpPWpGaD
Betamethasone—Gastrointestinal pain—Temozolomide—skin cancer	8.85e-05	0.00109	CcSEcCtD
Betamethasone—Erythema—Docetaxel—skin cancer	8.82e-05	0.00108	CcSEcCtD
Betamethasone—Dyspepsia—Fluorouracil—skin cancer	8.78e-05	0.00108	CcSEcCtD
Betamethasone—Decreased appetite—Fluorouracil—skin cancer	8.67e-05	0.00106	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Fluorouracil—skin cancer	8.61e-05	0.00106	CcSEcCtD
Betamethasone—Urticaria—Temozolomide—skin cancer	8.6e-05	0.00105	CcSEcCtD
Betamethasone—Asthenia—Dactinomycin—skin cancer	8.59e-05	0.00105	CcSEcCtD
Betamethasone—Abdominal pain—Temozolomide—skin cancer	8.56e-05	0.00105	CcSEcCtD
Betamethasone—Body temperature increased—Temozolomide—skin cancer	8.56e-05	0.00105	CcSEcCtD
Betamethasone—Pain—Fluorouracil—skin cancer	8.53e-05	0.00105	CcSEcCtD
Betamethasone—Feeling abnormal—Fluorouracil—skin cancer	8.22e-05	0.00101	CcSEcCtD
Betamethasone—Diarrhoea—Dactinomycin—skin cancer	8.19e-05	0.001	CcSEcCtD
Betamethasone—Vomiting—Bleomycin—skin cancer	8.16e-05	0.001	CcSEcCtD
Betamethasone—Rash—Bleomycin—skin cancer	8.09e-05	0.000993	CcSEcCtD
Betamethasone—Dermatitis—Bleomycin—skin cancer	8.09e-05	0.000992	CcSEcCtD
Betamethasone—NR3C1—Adipogenesis—PLIN2—skin cancer	8.07e-05	0.0148	CbGpPWpGaD
Betamethasone—ABCB1—lymph node—skin cancer	7.99e-05	0.00267	CbGeAlD
Betamethasone—Urticaria—Fluorouracil—skin cancer	7.93e-05	0.000972	CcSEcCtD
Betamethasone—Syncope—Docetaxel—skin cancer	7.91e-05	0.00097	CcSEcCtD
Betamethasone—Body temperature increased—Fluorouracil—skin cancer	7.89e-05	0.000967	CcSEcCtD
Betamethasone—Asthenia—Temozolomide—skin cancer	7.77e-05	0.000953	CcSEcCtD
Betamethasone—Loss of consciousness—Docetaxel—skin cancer	7.75e-05	0.000951	CcSEcCtD
Betamethasone—PLA2G1B—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	7.7e-05	0.0141	CbGpPWpGaD
Betamethasone—Pruritus—Temozolomide—skin cancer	7.66e-05	0.00094	CcSEcCtD
Betamethasone—Convulsion—Docetaxel—skin cancer	7.64e-05	0.000938	CcSEcCtD
Betamethasone—Nausea—Bleomycin—skin cancer	7.62e-05	0.000935	CcSEcCtD
Betamethasone—Hypertension—Docetaxel—skin cancer	7.62e-05	0.000934	CcSEcCtD
Betamethasone—Vomiting—Dactinomycin—skin cancer	7.61e-05	0.000934	CcSEcCtD
Betamethasone—Rash—Dactinomycin—skin cancer	7.55e-05	0.000926	CcSEcCtD
Betamethasone—Myalgia—Docetaxel—skin cancer	7.51e-05	0.000921	CcSEcCtD
Betamethasone—CYP19A1—Ovarian Infertility Genes—CDK4—skin cancer	7.5e-05	0.0138	CbGpPWpGaD
Betamethasone—ABCB1—HIF-1-alpha transcription factor network—PLIN2—skin cancer	7.46e-05	0.0137	CbGpPWpGaD
Betamethasone—Diarrhoea—Temozolomide—skin cancer	7.41e-05	0.000909	CcSEcCtD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—XRCC3—skin cancer	7.35e-05	0.0135	CbGpPWpGaD
Betamethasone—Oedema—Docetaxel—skin cancer	7.2e-05	0.000883	CcSEcCtD
Betamethasone—Anaphylactic shock—Docetaxel—skin cancer	7.2e-05	0.000883	CcSEcCtD
Betamethasone—Dizziness—Temozolomide—skin cancer	7.16e-05	0.000878	CcSEcCtD
Betamethasone—Infection—Docetaxel—skin cancer	7.15e-05	0.000877	CcSEcCtD
Betamethasone—Nausea—Dactinomycin—skin cancer	7.11e-05	0.000872	CcSEcCtD
Betamethasone—Shock—Docetaxel—skin cancer	7.08e-05	0.000869	CcSEcCtD
Betamethasone—Nervous system disorder—Docetaxel—skin cancer	7.06e-05	0.000866	CcSEcCtD
Betamethasone—Pruritus—Fluorouracil—skin cancer	7.06e-05	0.000866	CcSEcCtD
Betamethasone—Thrombocytopenia—Docetaxel—skin cancer	7.05e-05	0.000865	CcSEcCtD
Betamethasone—Tachycardia—Docetaxel—skin cancer	7.03e-05	0.000862	CcSEcCtD
Betamethasone—Vomiting—Temozolomide—skin cancer	6.88e-05	0.000844	CcSEcCtD
Betamethasone—Anorexia—Docetaxel—skin cancer	6.86e-05	0.000842	CcSEcCtD
Betamethasone—Rash—Temozolomide—skin cancer	6.83e-05	0.000837	CcSEcCtD
Betamethasone—Diarrhoea—Fluorouracil—skin cancer	6.83e-05	0.000837	CcSEcCtD
Betamethasone—Dermatitis—Temozolomide—skin cancer	6.82e-05	0.000837	CcSEcCtD
Betamethasone—Headache—Temozolomide—skin cancer	6.78e-05	0.000832	CcSEcCtD
Betamethasone—Hypotension—Docetaxel—skin cancer	6.73e-05	0.000825	CcSEcCtD
Betamethasone—Dizziness—Fluorouracil—skin cancer	6.6e-05	0.000809	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Docetaxel—skin cancer	6.56e-05	0.000805	CcSEcCtD
Betamethasone—Insomnia—Docetaxel—skin cancer	6.51e-05	0.000799	CcSEcCtD
Betamethasone—Paraesthesia—Docetaxel—skin cancer	6.47e-05	0.000793	CcSEcCtD
Betamethasone—Nausea—Temozolomide—skin cancer	6.43e-05	0.000789	CcSEcCtD
Betamethasone—Vomiting—Fluorouracil—skin cancer	6.34e-05	0.000778	CcSEcCtD
Betamethasone—Dyspepsia—Docetaxel—skin cancer	6.34e-05	0.000777	CcSEcCtD
Betamethasone—Rash—Fluorouracil—skin cancer	6.29e-05	0.000771	CcSEcCtD
Betamethasone—Dermatitis—Fluorouracil—skin cancer	6.28e-05	0.000771	CcSEcCtD
Betamethasone—Decreased appetite—Docetaxel—skin cancer	6.26e-05	0.000768	CcSEcCtD
Betamethasone—Headache—Fluorouracil—skin cancer	6.25e-05	0.000767	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Docetaxel—skin cancer	6.22e-05	0.000762	CcSEcCtD
Betamethasone—Fatigue—Docetaxel—skin cancer	6.21e-05	0.000761	CcSEcCtD
Betamethasone—Pain—Docetaxel—skin cancer	6.16e-05	0.000755	CcSEcCtD
Betamethasone—Feeling abnormal—Docetaxel—skin cancer	5.93e-05	0.000728	CcSEcCtD
Betamethasone—Dexamethasone—PTGS2—skin cancer	5.93e-05	0.036	CrCbGaD
Betamethasone—Nausea—Fluorouracil—skin cancer	5.93e-05	0.000727	CcSEcCtD
Betamethasone—Gastrointestinal pain—Docetaxel—skin cancer	5.89e-05	0.000722	CcSEcCtD
Betamethasone—Body temperature increased—Docetaxel—skin cancer	5.69e-05	0.000698	CcSEcCtD
Betamethasone—Abdominal pain—Docetaxel—skin cancer	5.69e-05	0.000698	CcSEcCtD
Betamethasone—PGR—Signaling by ERBB4—FOXO4—skin cancer	5.5e-05	0.0101	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—CSPG4—skin cancer	5.33e-05	0.00977	CbGpPWpGaD
Betamethasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOXO4—skin cancer	5.26e-05	0.00965	CbGpPWpGaD
Betamethasone—Asthenia—Docetaxel—skin cancer	5.17e-05	0.000634	CcSEcCtD
Betamethasone—Pruritus—Docetaxel—skin cancer	5.09e-05	0.000625	CcSEcCtD
Betamethasone—PLA2G1B—Fc-epsilon receptor I signaling in mast cells—HRAS—skin cancer	4.99e-05	0.00914	CbGpPWpGaD
Betamethasone—Diarrhoea—Docetaxel—skin cancer	4.93e-05	0.000604	CcSEcCtD
Betamethasone—Dizziness—Docetaxel—skin cancer	4.76e-05	0.000584	CcSEcCtD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—MSH2—skin cancer	4.73e-05	0.00868	CbGpPWpGaD
Betamethasone—Vomiting—Docetaxel—skin cancer	4.58e-05	0.000562	CcSEcCtD
Betamethasone—Rash—Docetaxel—skin cancer	4.54e-05	0.000557	CcSEcCtD
Betamethasone—Dermatitis—Docetaxel—skin cancer	4.54e-05	0.000556	CcSEcCtD
Betamethasone—Headache—Docetaxel—skin cancer	4.51e-05	0.000553	CcSEcCtD
Betamethasone—Nausea—Docetaxel—skin cancer	4.28e-05	0.000525	CcSEcCtD
Betamethasone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—skin cancer	3.51e-05	0.00643	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—RHOU—skin cancer	3.48e-05	0.00637	CbGpPWpGaD
Betamethasone—NR3C1—Transcription factor regulation in adipogenesis—IL6—skin cancer	3.48e-05	0.00637	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—PLIN2—skin cancer	3.43e-05	0.00628	CbGpPWpGaD
Betamethasone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—skin cancer	3.15e-05	0.00577	CbGpPWpGaD
Betamethasone—PTGS2—Overview of nanoparticle effects—IL6—skin cancer	2.96e-05	0.00543	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	2.81e-05	0.00515	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—CSPG4—skin cancer	2.76e-05	0.00506	CbGpPWpGaD
Betamethasone—NR3C1—AP-1 transcription factor network—CDKN2A—skin cancer	2.7e-05	0.00495	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	2.46e-05	0.00452	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	2.34e-05	0.00428	CbGpPWpGaD
Betamethasone—ABCB1—HIF-1-alpha transcription factor network—TERT—skin cancer	2.23e-05	0.00408	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—CDK4—skin cancer	2.17e-05	0.00397	CbGpPWpGaD
Betamethasone—PTGS2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	2.09e-05	0.00382	CbGpPWpGaD
Betamethasone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—skin cancer	1.99e-05	0.00364	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—BRAF—skin cancer	1.92e-05	0.00352	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—ENO2—skin cancer	1.88e-05	0.00344	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.88e-05	0.00344	CbGpPWpGaD
Betamethasone—PGR—Signaling by ERBB4—NRAS—skin cancer	1.83e-05	0.00335	CbGpPWpGaD
Betamethasone—PTGS2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	1.79e-05	0.00329	CbGpPWpGaD
Betamethasone—PTGS2—C-MYB transcription factor network—CDKN2A—skin cancer	1.77e-05	0.00325	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—CDK4—skin cancer	1.77e-05	0.00324	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	1.75e-05	0.0032	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—PTCH2—skin cancer	1.7e-05	0.00311	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	1.66e-05	0.00303	CbGpPWpGaD
Betamethasone—PGR—Signaling by ERBB4—KRAS—skin cancer	1.57e-05	0.00289	CbGpPWpGaD
Betamethasone—PTGS2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	1.53e-05	0.0028	CbGpPWpGaD
Betamethasone—NR3C1—AP-1 transcription factor network—TP53—skin cancer	1.5e-05	0.00276	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.47e-05	0.00269	CbGpPWpGaD
Betamethasone—NR3C1—AP-1 transcription factor network—IL6—skin cancer	1.38e-05	0.00252	CbGpPWpGaD
Betamethasone—PGR—Signaling by ERBB4—HRAS—skin cancer	1.34e-05	0.00245	CbGpPWpGaD
Betamethasone—NR3C1—Glucocorticoid receptor regulatory network—TP53—skin cancer	1.33e-05	0.00243	CbGpPWpGaD
Betamethasone—PTGS2—C-MYB transcription factor network—NRAS—skin cancer	1.29e-05	0.00236	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—GLI2—skin cancer	1.29e-05	0.00236	CbGpPWpGaD
Betamethasone—NR3C2—Gene Expression—ERCC2—skin cancer	1.28e-05	0.00235	CbGpPWpGaD
Betamethasone—PGR—Signaling by ERBB4—IL6—skin cancer	1.28e-05	0.00235	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PLIN2—skin cancer	1.25e-05	0.00229	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—MC1R—skin cancer	1.23e-05	0.00225	CbGpPWpGaD
Betamethasone—NR3C1—Glucocorticoid receptor regulatory network—IL6—skin cancer	1.21e-05	0.00222	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—GLI1—skin cancer	1.21e-05	0.00222	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.2e-05	0.0022	CbGpPWpGaD
Betamethasone—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	1.2e-05	0.0022	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—SUFU—skin cancer	1.15e-05	0.0021	CbGpPWpGaD
Betamethasone—PTGS2—C-MYB transcription factor network—KRAS—skin cancer	1.11e-05	0.00203	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—ERCC2—skin cancer	1.09e-05	0.002	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—KRAS—skin cancer	1.04e-05	0.0019	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—CSPG4—skin cancer	1.01e-05	0.00185	CbGpPWpGaD
Betamethasone—PTGS2—C-MYB transcription factor network—HRAS—skin cancer	9.42e-06	0.00173	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—TP53—skin cancer	9.23e-06	0.00169	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—SHH—skin cancer	8.75e-06	0.0016	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—RASA1—skin cancer	8.69e-06	0.00159	CbGpPWpGaD
Betamethasone—PTGS2—Selenium Micronutrient Network—IL6—skin cancer	8.69e-06	0.00159	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	8.51e-06	0.00156	CbGpPWpGaD
Betamethasone—NR3C1—Adipogenesis—IL6—skin cancer	8.39e-06	0.00154	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PLIN2—skin cancer	8.36e-06	0.00153	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—SMO—skin cancer	8.29e-06	0.00152	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—PTCH1—skin cancer	8.29e-06	0.00152	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—PTGER4—skin cancer	8.07e-06	0.00148	CbGpPWpGaD
Betamethasone—PTGS2—Disease—CSPG4—skin cancer	8.05e-06	0.00148	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—ERCC2—skin cancer	7.81e-06	0.00143	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—TP53—skin cancer	7.51e-06	0.00138	CbGpPWpGaD
Betamethasone—NR3C1—SIDS Susceptibility Pathways—IL6—skin cancer	7.25e-06	0.00133	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—FOXO4—skin cancer	7.13e-06	0.00131	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—IL6—skin cancer	6.87e-06	0.00126	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—ENO2—skin cancer	6.86e-06	0.00126	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—CSPG4—skin cancer	6.74e-06	0.00124	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—PTGS2—skin cancer	6.54e-06	0.0012	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	6.08e-06	0.00111	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PLIN2—skin cancer	5.93e-06	0.00109	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	5.75e-06	0.00105	CbGpPWpGaD
Betamethasone—PTGS2—Disease—SHH—skin cancer	5.47e-06	0.001	CbGpPWpGaD
Betamethasone—PTGS2—Disease—ENO2—skin cancer	5.47e-06	0.001	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	5.36e-06	0.000983	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	5.11e-06	0.000936	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CSPG4—skin cancer	4.78e-06	0.000876	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—TERT—skin cancer	4.76e-06	0.000873	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—ENO2—skin cancer	4.58e-06	0.00084	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—ERCC2—skin cancer	4.52e-06	0.000828	CbGpPWpGaD
Betamethasone—PTGS2—Disease—FOXO4—skin cancer	4.46e-06	0.000817	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	4.07e-06	0.000747	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—ERCC2—skin cancer	3.98e-06	0.00073	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—BRAF—skin cancer	3.77e-06	0.000691	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PLIN2—skin cancer	3.65e-06	0.000669	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	3.62e-06	0.000664	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—ENO2—skin cancer	3.25e-06	0.000595	CbGpPWpGaD
Betamethasone—PTGS2—Disease—ERCC2—skin cancer	3.18e-06	0.000582	CbGpPWpGaD
Betamethasone—PTGS2—Disease—TERT—skin cancer	2.98e-06	0.000546	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—CSPG4—skin cancer	2.94e-06	0.00054	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—ERCC2—skin cancer	2.66e-06	0.000488	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PTGS2—skin cancer	2.39e-06	0.000438	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—NRAS—skin cancer	2.37e-06	0.000434	CbGpPWpGaD
Betamethasone—PTGS2—Disease—BRAF—skin cancer	2.36e-06	0.000432	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—KRAS—skin cancer	2.04e-06	0.000374	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—ENO2—skin cancer	2e-06	0.000367	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—ERCC2—skin cancer	1.89e-06	0.000346	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—TP53—skin cancer	1.81e-06	0.000332	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—HRAS—skin cancer	1.73e-06	0.000318	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—IL6—skin cancer	1.66e-06	0.000304	CbGpPWpGaD
Betamethasone—PTGS2—Disease—NRAS—skin cancer	1.48e-06	0.000272	CbGpPWpGaD
Betamethasone—PTGS2—Disease—KRAS—skin cancer	1.28e-06	0.000234	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—ERCC2—skin cancer	1.16e-06	0.000213	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PTGS2—skin cancer	1.13e-06	0.000207	CbGpPWpGaD
Betamethasone—PTGS2—Disease—HRAS—skin cancer	1.08e-06	0.000199	CbGpPWpGaD
Betamethasone—PTGS2—Disease—IL6—skin cancer	1.04e-06	0.00019	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PTGS2—skin cancer	6.97e-07	0.000128	CbGpPWpGaD
